Sentences with phrase «in cell therapy applications»

Embryonic stem (ES) cells are important tools in the study of gene function and may also become important in cell therapy applications.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Even more applications for cell therapies beyond cancer could become reality in the coming years.

Investigations aimed at determining the downstream targets of LIF would help to clarify the functional importance of LIF in muscle regeneration, and further its potential application in cell transplantation therapy.»

The present and potential clinical applications of mesenchymal stem cell therapy in cats are explored in a state - of - the - art review article published this month in the Journal of Feline Medicine and Surgery.

«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.

For these cells to be as useful as embryonic stem cells, «we have to find a way to avoid retroviruses before application in cell therapy», Yamanaka says, as they could result in tumours.

To the Editor: In their Clinical Review, Dr Burt and colleagues1 assessed clinical applications of adult stem cell therapies for nonmalignant diseases.

Furthermore, this study also encourages the application of iPSC - MSCs as an exciting new therapeutic option for a range of immunological disorders and suggests that further study of the secreted factors may allow the construction of efficient cell - free therapies in the near future.

Intellia is developing human gene and cell therapies for both ex vivo and in vivo applications using CRISPR - Cas9 gene editing technology.

In parallel to this cell therapy application, keratynocytes and melanocytes derived from pluripotent stem cells will be used for pathological modelling of genodermatoses allowing identification of new disease - specific pharmacological treatments

The symposium brings together leaders in biology, medicine, and industry to present on the latest advances in technology development, mechanistic understanding, and therapeutic application of stem cells for both drug development and cell - based therapy.

San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign.

Zernicka - Goetz's research could also lead to important advancements in the study of embryonic stem cell therapy applications.

This spotlight on cell therapy regulation will aim to provide insight into challenges, trends, developments and debates in the regulation of cell therapies aimed at regenerative medicine applications.

The long - term vision is to apply these technologies to other genetic diseases, such as sickle cell disease, and to explore applications in developing effective immune therapies for cancer.

«I highly respect Novocell technologies and am pleased to collaborate with Novocell and explore the potential of their hES cell to islet cell advances in combination with our iPS cells as a potential new sources for the generation of cellular models and therapies for diabetes,» said Dr. Yamanaka, Director of Center for iPS Research and Application at Kyoto University.

That has been in part a result of how much response efficacy that has been achieved with some patients in addition to work with different types of gene therapy applications and coupling those with cell therapy advancements.

The Bulte Lab has developed methods to label cells magnetically using tiny superparamagnetic iron oxide nanoparticles in order to make them visible by magnetic resonance imaging; this technology has now been introduced in the clinic for several cell therapy applications.

«Having a very efficient and practical way of generating patient - specific stem cells, which unlike human embryonic stem cells, wouldn't be rejected by the patient's immune system after transplantation brings us a step closer to the clinical application of stem cell therapy,» says Belmonte, PhD., a professor in the Gene Expression Laboratory and director of the Center of Regenerative Medicine in Barcelona, Spain.

A promising clinical application for stem and progenitor cell transplantation is in rescue therapy for degenerative diseases.

«Finding this population of stem cells in a human source represents a major breakthrough for us because it brings us much closer to a clinical application of this therapy,» said Dr. Huard, the Henry J. Mankin Professor and vice chair for Research in the Department of Orthopaedic Surgery at the University of Pittsburgh School of Medicine.

It is conceivable the techniques being developed might have some application in future stem cell therapies in humans where a cloning process was used to generate particular tissues for transplantation.

The advent of human induced pluripotent stem cells has been heralded as a major breakthrough in the study of pluripotent stem cells, for these cells have yielded fundamental insights into the reprogrammability of somatic cell fates, but also because of their seemingly great promise in applications, including potential uses in cell therapy.

Initially founded in 2011 as a Heart Institute, our treatment protocols were later expanded to include adult stem cell therapy for patients with severe and chronic medical needs that, per scientific research, clinical trials and application, can be safely and potentially efficaciously treated with patients» own stem and regenerative cells.

Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.

Importantly, because it is already approved for clinical use, amiodarone HCL may have clinical applications in cell replacement therapies by selectively removing only the unwanted undifferentiated NSCs during the pre-transplant period.

«The proposed experiments, if successful, will address an important unmet need in bringing stem cell therapies to clinical use and provide the foundation for a wide range of additional applications,» Clegg said.

In a review published in the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in catIn a review published in the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in catin the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in catin cats.